For the second quarter of 2026, analysts expect Cue Biopharma to report a consensus loss of $1.38 per share on revenue of $3.0 million, with the current stock price of $27.12 trading significantly below the average analyst target of $117.30.
Investors are primarily focused on clinical updates for CUE-221, the company's lead anti-IgE program, following recently updated guidance that Phase 2 data is now expected by the end of the third quarter.
The report follows a successful $50 million private placement in July 2026, which strengthened the balance sheet and extended the company's cash runway under new CEO Shao-Lee Lin. Management is expected to provide further details on the development milestones for CUE-401 as the company transitions its precision immuno-engineering portfolio deeper into clinical stages.